Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18648047 | 0.87 | TAAR1 (0.47) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL12188934 | 0.81 | PARP1 (0.41) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL13146605 | 0.80 | ALDH1A1 (0.48) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL700254 | 0.78 | CYP3A4 (0.40) | TAAR1SLC6A4CYP2D6CYP3A4GAA | |
| SCHEMBL19601665 | 0.78 | GABRA1 (0.43) | TAAR1SLC6A4SLC6A2SLC6A3GABRA1 | |
| SCHEMBL104467 | 0.78 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL25837105 | 0.77 | ESR1 (0.35) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL11477974 | 0.77 | CHRM2 (0.50) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL70621 | 0.75 | MEN1 (0.37) | CYP2D6NPSR1CYP3A4GAAMAPT | |
| SCHEMBL19465751 | 0.74 | KCNH2 (0.46) | TAAR1SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | TAAR1 1464/4885SLC6A4 4212/4885SLC6A2 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.